Pharmacogenomics in Cytotoxic Chemotherapy of Cancer

Zahra Talebi; Alex Sparreboom; Susan I Colace

doi:10.1007/978-1-0716-2573-6_4

Pharmacogenomics in Cytotoxic Chemotherapy of Cancer

Methods Mol Biol. 2022:2547:63-94. doi: 10.1007/978-1-0716-2573-6_4.

Authors

Zahra Talebi¹, Alex Sparreboom², Susan I Colace^{3

4}

Affiliations

¹ Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
² Division of Pharmaceutics and Pharmacology, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
³ Division of Hematology, Oncology, and Blood & Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA. susan.colace@nationwidechildrens.org.
⁴ The Ohio State University, Columbus, OH, USA. susan.colace@nationwidechildrens.org.

PMID: 36068461
DOI: 10.1007/978-1-0716-2573-6_4

Abstract

Pharmacogenetic testing in patients with cancer requiring cytotoxic chemotherapy offers the potential to predict, prevent, and mitigate chemotherapy-related toxicities. While multiple drug-gene pairs have been identified and studied, few drug-gene pairs are currently used routinely in the clinical status. Here we review what is known, theorized, and unknown regarding the use of pharmacogenetic testing in cancer.

Keywords: Cancer; Chemotherapy; Efficacy; Pharmacogenetics; Pharmacogenomics; Toxicity.

Publication types

Review

MeSH terms

Humans
Neoplasms* / drug therapy
Neoplasms* / genetics
Pharmacogenetics*
Pharmacogenomic Testing